|
 Two experimental drugs - Regeneron's <REGN.O> REGN-EB3 and a
monoclonal antibody called mAb114 - were both developed using
antibodies harvested from survivors of Ebola infection.
The treatments are now going to be offered to all patients in the
Democratic Republic of Congo (DRC), according to U.S. National
Institute of Allergy and Infectious Diseases.
They showed "clearly better" results in patients in a trial of four
potential treatments being conducted during the world's second
largest Ebola outbreak in history, now entering its second year in
DRC.
The drugs improved survival rates from the disease more than two
other treatments being tested - ZMapp, made by Mapp
Biopharmaceutical, and Remdesivir, made by Gilead Sciences <GILD.O>
- and those products will be now dropped, said Anthony Fauci, one of
the researchers co-leading the trial.
The agency said 49% of the patients on ZMapp and 53% on remdesivir
died in the study. In comparison, 29% of the patients on REGN-EB3
and 34% on mAb-114 died.
Fauci, director of the U.S. National Institute of Allergy and
Infectious Diseases, told reporters in a telebriefing the results
were "very good news" for the fight against Ebola.
"What this means is that we do now have what look like (two)
treatments for a disease for which not long ago we really had no
approach at all," he said.
The agency said of the patients who were brought into treatment
centres with low levels of virus detected in their blood, 94% who
got REGN-EB3 and 89% on mAb114 survived.
In comparison, two-third of the patients who got remdesivir and
nearly three-fourth on ZMapp survived.
Ebola has been spreading in eastern Congo since August 2018 in an
outbreak that has now become the second largest, killing at least
1,800 people. Efforts to control it have been hampered by militia
violence and some local resistance to outside help.
[to top of second column] |
A vast Ebola outbreak in West Africa become the world's largest ever
when it spread through Guinea, Liberia and Sierra Leone from 2013 to
2016 and killed more than 11,300 people.
The Congo treatment trial, which began in November last year, is
being carried out by an international research group coordinated by
the World Health Organization (WHO).
Mike Ryan, head of the WHO's emergencies program, said the trial's
positive findings were encouraging but would not be enough on their
own to bring the epidemic to an end.
"The news today is fantastic. It gives us a new tool in our toolbox
against Ebola, but it will not in itself stop Ebola," he told
reporters.
Jeremy Farrar, director of the Wellcome Trust global health charity,
also hailed the success of the trial's findings, saying they would
"undoubtedly save lives".
"The more we learn about these two treatments, ...the closer we can
get to turning Ebola from a terrifying disease to one that is
preventable and treatable," he said in a statement.
"We won't ever get rid of Ebola but we should be able to stop these
outbreaks from turning into major national and regional epidemics."
Some 681 patients at four separate treatment centres in Congo have
already been enrolled in the Congo treatment clinical trial, Fauci
said. The study aims to enrol a total of 725.
The decision to drop two of the trial drugs was based on data from
almost 500 patients, he said, which showed that those who got
REGN-EB3 or mAb114 "had a greater chance of survival compared to
those participants in the other two arms".
(Reporting by Kate Kelland, additional reporting by Ankur Banerjee
and Manojna Maddipatla ; Editing by Deepa Babington, Mark Heinrich
and Arun Koyyur)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
